Decoy Therapeutics Secures $3.5 Million PIPE Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Financing Agreement: Decoy Therapeutics has entered into a securities purchase agreement with a healthcare-focused institutional investor, expected to provide approximately $3.5 million in financing, which will be used to advance its lead asset into clinical trials, indicating the company's proactive development in the biotech sector.
- Financing Structure Details: The financing includes $3.5 million from the sale of common stock at a price of $5.91 per share, along with milestone-based warrants that could yield an additional $3.5 million to $7 million if fully exercised, reflecting the company's confidence in future clinical trials.
- Clinical Trial Plans: The company intends to submit a Clinical Trial Application to the regulatory authority in the European Economic Area after obtaining shareholder approval to initiate a Phase 1 clinical trial, which, if successful, will further propel the market entry of its antiviral drugs and enhance competitive positioning.
- Market Compliance: This financing is made under the exemption provisions of Section 4(a)(2) of the Securities Act of 1933, demonstrating the company's commitment to compliance, while planning to file a registration statement with the SEC within 15 days post-closing to ensure future liquidity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DCOY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DCOY
About DCOY
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Decoy Therapeutics Secures $3.5 Million PIPE Financing
- Financing Agreement: Decoy Therapeutics has entered into a securities purchase agreement with a healthcare-focused institutional investor, expected to provide approximately $3.5 million in financing, which will be used to advance its lead asset into clinical trials, indicating the company's proactive development in the biotech sector.
- Financing Structure Details: The financing includes $3.5 million from the sale of common stock at a price of $5.91 per share, along with milestone-based warrants that could yield an additional $3.5 million to $7 million if fully exercised, reflecting the company's confidence in future clinical trials.
- Clinical Trial Plans: The company intends to submit a Clinical Trial Application to the regulatory authority in the European Economic Area after obtaining shareholder approval to initiate a Phase 1 clinical trial, which, if successful, will further propel the market entry of its antiviral drugs and enhance competitive positioning.
- Market Compliance: This financing is made under the exemption provisions of Section 4(a)(2) of the Securities Act of 1933, demonstrating the company's commitment to compliance, while planning to file a registration statement with the SEC within 15 days post-closing to ensure future liquidity.
See More
Decoy Therapeutics Secures $3.5 Million PIPE Financing
- Financing Agreement: Decoy Therapeutics has entered into a securities purchase agreement with a single healthcare-focused institutional investor, expected to yield approximately $3.5 million in gross proceeds, which will be utilized to advance its lead asset into clinical trials, indicating the company's ongoing growth potential in the antiviral sector.
- Equity Issuance Details: The financing involves the sale of common stock at a price of $5.91 per share, along with milestone-based warrants that could generate additional proceeds of $3.5 million to $7 million if fully exercised, reflecting the company's confidence in the success of future clinical trials.
- Regulatory Compliance Measures: This financing is made under the exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933, with a registration statement to be filed with the SEC within 15 days post-closing, ensuring compliance and paving the way for future capital market activities.
- Market Outlook: Decoy Therapeutics is focused on developing antiviral drugs targeting multiple respiratory viruses using its proprietary IMP(3)ACT platform, which is expected to accelerate product entry into clinical phases and further solidify its market position in the biotechnology field.
See More
Decoy Therapeutics Nominates New Director
- New Board Nomination: Decoy Therapeutics has nominated Patricia Gauthier as a Class II director, with a vote scheduled for the July 14, 2026 Annual Meeting, aiming to leverage her extensive experience in biomanufacturing and national health security partnerships to advance D-MAV programs into clinical stages.
- Extensive Industry Background: Since 2025, Gauthier has served as Senior Vice President at Moderna, overseeing strategy and operations across Australia, Canada, and the UK, successfully delivering over 50 million COVID-19 vaccine doses and securing a landmark biomanufacturing partnership with the Canadian government, showcasing her leadership in the vaccine sector.
- Antiviral Drug Innovation: Gauthier emphasizes that Decoy's D-MAV approach offers a robust model for adaptable antiviral medicines by targeting shared viral mechanisms, potentially expanding the possibilities in viral prevention and treatment, which aligns with the global demand for new antiviral solutions.
- Strategic Company Development: This nomination not only recognizes Gauthier's capabilities but also reflects Decoy Therapeutics' strategic intent to enhance its influence in the global health market, aiming to address future viral threats through its innovative antiviral drug pipeline.
See More
Decoy Therapeutics Partners with hVIVO for D-MAV Clinical Development
- Strategic Partnership: Decoy Therapeutics has entered into a strategic development agreement with European pharmaceutical service partner hVIVO plc to advance its lead D-MAV candidate into Phase 1 first-in-human and Phase 2a proof-of-concept studies, marking a significant step in addressing respiratory viral infections.
- Regulatory Support: Under the agreement, hVIVO will provide Decoy with regulatory strategy, translational modeling, scientific advice preparation, CMC consulting, and non-clinical development support, ensuring smooth clinical trial submissions in Europe and the UK, thereby accelerating the drug's market entry.
- Clinical Development Planning: Decoy intends to leverage the data generated to update its clinical development strategy, including Phase 1 dose selection, translational pharmacology planning, and challenge study design considerations, ensuring effective progression of its D-MAV programs.
- Long-term Goals: This collaboration not only supports early clinical execution and regulatory planning but also lays the groundwork for future IND/CTA filings with the FDA, demonstrating Decoy's strategic positioning for the global market.
See More
Decoy Therapeutics Initiates Clinical Studies for New Antiviral Category
- Strategic Collaboration: Decoy Therapeutics has signed an agreement with hVIVO to support its Designable Multi-Antiviral (D-MAV) candidates in Phase 1 and Phase 2a clinical studies, marking a significant advancement in the antiviral sector.
- Clinical Development Support: hVIVO will provide comprehensive support including translational modeling, regulatory strategy, and clinical development planning, ensuring smooth preparation for D-MAV candidates' clinical trials, thereby accelerating the drug's path to market.
- Innovative Platform Utilization: Decoy's IMP³ACT™ platform integrates AI-driven peptide design with rapid synthesis technology, enabling D-MAV candidates to enter clinical trials more swiftly, enhancing the ability to respond to emerging viral threats.
- Market Potential Outlook: Decoy plans to leverage the outputs from its collaboration with hVIVO to facilitate the registration of its D-MAV candidates in the US and Europe, aiming to address multiple respiratory viruses with a single adaptable therapeutic approach to meet global health needs.
See More
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
Decoy Therapeutics Secures $3.5 Million PIPE Financing
- Financing Agreement: Decoy Therapeutics has entered into a securities purchase agreement with a healthcare-focused institutional investor, expected to provide approximately $3.5 million in financing, which will be used to advance its lead asset into clinical trials, indicating the company's proactive development in the biotech sector.
- Financing Structure Details: The financing includes $3.5 million from the sale of common stock at a price of $5.91 per share, along with milestone-based warrants that could yield an additional $3.5 million to $7 million if fully exercised, reflecting the company's confidence in future clinical trials.
- Clinical Trial Plans: The company intends to submit a Clinical Trial Application to the regulatory authority in the European Economic Area after obtaining shareholder approval to initiate a Phase 1 clinical trial, which, if successful, will further propel the market entry of its antiviral drugs and enhance competitive positioning.
- Market Compliance: This financing is made under the exemption provisions of Section 4(a)(2) of the Securities Act of 1933, demonstrating the company's commitment to compliance, while planning to file a registration statement with the SEC within 15 days post-closing to ensure future liquidity.
See More
Decoy Therapeutics Secures $3.5 Million PIPE Financing
- Financing Agreement: Decoy Therapeutics has entered into a securities purchase agreement with a single healthcare-focused institutional investor, expected to yield approximately $3.5 million in gross proceeds, which will be utilized to advance its lead asset into clinical trials, indicating the company's ongoing growth potential in the antiviral sector.
- Equity Issuance Details: The financing involves the sale of common stock at a price of $5.91 per share, along with milestone-based warrants that could generate additional proceeds of $3.5 million to $7 million if fully exercised, reflecting the company's confidence in the success of future clinical trials.
- Regulatory Compliance Measures: This financing is made under the exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933, with a registration statement to be filed with the SEC within 15 days post-closing, ensuring compliance and paving the way for future capital market activities.
- Market Outlook: Decoy Therapeutics is focused on developing antiviral drugs targeting multiple respiratory viruses using its proprietary IMP(3)ACT platform, which is expected to accelerate product entry into clinical phases and further solidify its market position in the biotechnology field.
See More
Decoy Therapeutics Nominates New Director
- New Board Nomination: Decoy Therapeutics has nominated Patricia Gauthier as a Class II director, with a vote scheduled for the July 14, 2026 Annual Meeting, aiming to leverage her extensive experience in biomanufacturing and national health security partnerships to advance D-MAV programs into clinical stages.
- Extensive Industry Background: Since 2025, Gauthier has served as Senior Vice President at Moderna, overseeing strategy and operations across Australia, Canada, and the UK, successfully delivering over 50 million COVID-19 vaccine doses and securing a landmark biomanufacturing partnership with the Canadian government, showcasing her leadership in the vaccine sector.
- Antiviral Drug Innovation: Gauthier emphasizes that Decoy's D-MAV approach offers a robust model for adaptable antiviral medicines by targeting shared viral mechanisms, potentially expanding the possibilities in viral prevention and treatment, which aligns with the global demand for new antiviral solutions.
- Strategic Company Development: This nomination not only recognizes Gauthier's capabilities but also reflects Decoy Therapeutics' strategic intent to enhance its influence in the global health market, aiming to address future viral threats through its innovative antiviral drug pipeline.
See More
Decoy Therapeutics Partners with hVIVO for D-MAV Clinical Development
- Strategic Partnership: Decoy Therapeutics has entered into a strategic development agreement with European pharmaceutical service partner hVIVO plc to advance its lead D-MAV candidate into Phase 1 first-in-human and Phase 2a proof-of-concept studies, marking a significant step in addressing respiratory viral infections.
- Regulatory Support: Under the agreement, hVIVO will provide Decoy with regulatory strategy, translational modeling, scientific advice preparation, CMC consulting, and non-clinical development support, ensuring smooth clinical trial submissions in Europe and the UK, thereby accelerating the drug's market entry.
- Clinical Development Planning: Decoy intends to leverage the data generated to update its clinical development strategy, including Phase 1 dose selection, translational pharmacology planning, and challenge study design considerations, ensuring effective progression of its D-MAV programs.
- Long-term Goals: This collaboration not only supports early clinical execution and regulatory planning but also lays the groundwork for future IND/CTA filings with the FDA, demonstrating Decoy's strategic positioning for the global market.
See More
Decoy Therapeutics Initiates Clinical Studies for New Antiviral Category
- Strategic Collaboration: Decoy Therapeutics has signed an agreement with hVIVO to support its Designable Multi-Antiviral (D-MAV) candidates in Phase 1 and Phase 2a clinical studies, marking a significant advancement in the antiviral sector.
- Clinical Development Support: hVIVO will provide comprehensive support including translational modeling, regulatory strategy, and clinical development planning, ensuring smooth preparation for D-MAV candidates' clinical trials, thereby accelerating the drug's path to market.
- Innovative Platform Utilization: Decoy's IMP³ACT™ platform integrates AI-driven peptide design with rapid synthesis technology, enabling D-MAV candidates to enter clinical trials more swiftly, enhancing the ability to respond to emerging viral threats.
- Market Potential Outlook: Decoy plans to leverage the outputs from its collaboration with hVIVO to facilitate the registration of its D-MAV candidates in the US and Europe, aiming to address multiple respiratory viruses with a single adaptable therapeutic approach to meet global health needs.
See More
Decoy Appoints New Chair of Scientific Advisory Board
- Enhanced Scientific Leadership: Decoy Therapeutics has appointed Dr. Brad L. Pentelute, a Professor at MIT, as Chair of its Scientific Advisory Board, aiming to advance the clinical development of its Designable Multi-Antivirals (D-MAVs™) and strengthen its competitive position in the antiviral sector.
- Innovation-Driven Technology: Dr. Pentelute's research focuses on rapid flow peptide synthesis and intracellular delivery, which, combined with Decoy's IMP3ACT™ platform, is expected to significantly shorten development timelines and enhance market responsiveness for drug candidates.
- Strategic Direction Guidance: As Chair of the SAB, Dr. Pentelute will leverage his extensive knowledge in peptide therapeutics to guide Decoy's scientific direction, helping the company pioneer new pathways in multi-viral targeting therapies and drive innovation in antiviral drug development.
- Positive Outlook Ahead: Decoy's D-MAVs™ aim to disrupt the traditional one-virus, one-drug model by designing across shared viral mechanisms, which is anticipated to bring revolutionary changes to global antiviral treatment and meet the increasing public health demands.
See More
